Asher Bio Raises $108m For Immune Cell-Specific Therapies

Series B Follows $55m Series A Round In March

 
• By Mandy Jackson
Blue and green "venture capital" neon light
Asher Bio will use its funding to take lead program AB248 into the clinic • Source: Alamy

More from Financing

More from Business